Court Approves 23andMe Sale to Ex-CEO's Nonprofit

Court Approves 23andMe Sale to Ex-CEO's Nonprofit
Above: 23andMe founder Anne Wojcicki appears before the U.S. Congress on June 10, 2025. Image credit: Andrew Harnik/Getty Images

The Facts

  • A bankruptcy court this week approved the $305 million sale of genetics testing firm 23andMe to TTAM Research Institute, a nonprofit organization led by 23andMe's co-founder and former CEO Anne Wojcicki, replacing a previous $256 million bid from Regeneron Pharmaceuticals announced in May.
  • This sale involves the genetic data of over 15 million customers and includes 23andMe's Personal Genome Service, Research Service, and Lemonaid Health business. The transaction is expected to close after approval from a U.S. bankruptcy judge.
  • Twenty-seven states and Washington, D.C. in June filed a lawsuit to block the sale of customers' genetic information without their consent. Though many states resolved their concerns, California, Kentucky, Tennessee, Texas, and Utah remain actively opposed to the transaction.

Sources Split


The Spin


Narrative A

This sale protects consumer privacy by keeping genetic data under the same leadership that built the company's privacy framework. Wojcicki's nonprofit structure ensures data won't be exploited for profit. The enhanced privacy protections actually strengthen consumer safeguards beyond what existed before.

Narrative B

This court approval sets a dangerous precedent for selling sensitive genetic data without explicit customer consent, exposing loopholes in privacy laws. Despite its nonprofit status, the transfer still violates state privacy statutes and creates regulatory uncertainty about future data protection.

© 2026 Improve the News Foundation. All rights reserved.Version 7.18.2

© 2026 Improve the News Foundation.

All rights reserved.

Version 7.18.2